LDE225 0.75%

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Sporadic Superficial and Nodular Skin Basal Cell CarcinomasTreatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients

Phase 2

A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

CompletedNCT00961896

Novartis PharmaceuticalsTreatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients

Start: 2009-07-31Updated: 2015-11-03

To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)

TerminatedNCT01033019

Novartis PharmaceuticalsSporadic Superficial and Nodular Skin Basal Cell Carcinomas

Start: 2009-12-31End: 2011-02-28Updated: 2015-10-30